Merck & Co., Inc. (MRK) — closed signal from August 30, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on November 28, 2025.
Predicted vs. what happened
What happened
Reached its target in 76 days.
The thesis — published August 30, 2025
Merck offers steady income plus room to grow. The recent average price is edging up, suggesting interest is improving, so buying in small steps fits. Merck will buy Verona Pharma for about $10B, adding lung-related drugs and research. VERQUVO trial results were mixed, but a strong dividend and the freedom to keep making smart deals could support a gradual rise over the next three months.
Primary drivers
- Reliable dividend gives steady income and helps cushion downturns
- Recent average price is gently rising, hinting at improving interest
- Buying Verona Pharma adds new lung drugs and future product options
- Some study results are mixed, so keep position size moderate
How it played out
MRK: target reached in 76 days
Lyra published MRK at $82.59 on 2025-08-30 with expected growth of 14%. The thesis pointed to steady income from the dividend, a gently rising recent average price, the planned Verona Pharma purchase for about $10B, and mixed VERQUVO study results as a reason to keep position size moderate.
Inside the window, MRK reached the $92.44 target in 76 days. It later peaked at $104.94 on 2025-11-25, with a peak gain of 27.1%. The window ended at $103.94 on 2025-11-28. The thesis played out, and the move went beyond the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.